secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2024-12-26T23:59:59+00:00
Accession:  0001493152-24-052104
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Launches Generic Vyvanse (Lisdexamfetamine) in 7 Strengths for ADHD
-------------------------------------------------------------------------

- Elite launched generic lisdexamfetamine (Vyvanse) in 10, 20, 30, 40, 50, 60, 70 mg capsules.
- Branded Vyvanse annual sales ~$4.3B (12 months ending Oct 2024, per IQVIA).
- Product marketed under Elite Laboratories label; company operates cGMP/DEA facility in Northvale, NJ.
- This generic version is indicated for treatment of attention deficit hyperactivity disorder (ADHD).
- Launch represents expansion of Elite's niche generic product portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224052104/0001493152-24-052104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315224052104/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-052104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer